An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.
Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.Â
A study from New York University researchers found that cancer cells work together to source nutrients from their environment—a cooperative process that was previously overlooked by scientists but may be a promising target for treating cancer. The study was published in Nature.
Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.Â
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood—known as the tertiary lymphoid structure—where they become dysfunctional when in close contact with tumors. Â
Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.
FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.
Indirect costs are a component of a grant award that recognizes expenses for a project that, for efficiency’s sake, are aggregated across projects and divided proportionally to projects rather than explicitly charged to each project. They are influenced by location and services provided.
Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
Aleksandar Sekulic was named physician-in-chief at the Translational Genomics Research Institute, part of City of Hope.Â
